Clinical trials: Neovascular Age-related Macular Degeneration
Neovascular Age-Related Macular Degeneration
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
The PrONTO Study was designed to evaluate the response of neovascular age-related macular degeneration (AMD) patients to intravitreal Lucentis using Optical Coherence Tomography (OCT) imaging.
- Trial name
- NCT00344227
- Testing
- Lucentis (Ranibizumab)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Age-Related Macular Degeneration
Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.
A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.
- Trial name
- NCT00148551
- Testing
- Triamcinolone Acetonide
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Canadian Retinal Trials Group
Exudative Age-related Macular Degeneration
Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab
This study evaluates the retinal and vascular features in patients with macular degeneration under the effects of Bevacizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography.
- Trial name
- NCT04138420
- Testing
- Bevacizumab Injection
- Where
- Italy
- Volunteers
- 38 people
- Sponsor
- Federico II University
Age Related Macular Degeneration, Diabetic Macular Edema
Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept
Objective: To determine the association between baseline aqueous cytokine levels and treatment intervals for patients under a variable dosing regimen with intravitreal aflibercept in patients with neovascular age-related macular…
- Conditions
- Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Macular Edema
- Trial name
- COVARIANT (NCT03056079)
- Testing
- Intravitreal aflibercept
- Where
- 2 sites in Canada
- Volunteers
- 168 people
- Sponsor
- Unity Health Toronto
Macular Degeneration
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Part A (Phase IIa): Primary objectives: The study part A is designed to investigate whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4…
- Trial name
- DREAM (NCT02222207)
- Testing
- Regorafenib, ophthalmic oily suspension (BAY73-4506), Ranibizumab
- Where
- 149 sites in United States, Australia and 16 more
- Volunteers
- 52 people
- Sponsor
- Bayer
Age-related Macular Degeneration (AMD)
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
This was the cross-sectional study to assess the period prevalence of IOI in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period in 2019.
- Trial name
- NCT05146687
- Testing
- Aflibercept, Ranibizumab, Bevacizumab
- Where
- United States
- Volunteers
- 369,600 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-Related Macular Degeneration
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) in patients suffering from neovascular age-related macular degeneration (nAMD).
- Trial name
- PULSAR (NCT04423718)
- Testing
- Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
- Where
- 235 sites in United States, Argentina and 25 more
- Volunteers
- 1,011 people
- Sponsor
- Bayer
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Study of DS-7080a for the Treatment of Macular Degeneration
The purpose of this study is to test DS-7080a, a monoclonal antibody, as a new treatment for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME).
- Trial name
- NCT02530918
- Testing
- DS-7080a, Ranibizumab
- Where
- 12 sites in United States
- Volunteers
- 56 people
- Sponsor
- Daiichi Sankyo
Neovascular (wet) Age-Related Macular Degeneration
The Effect of Phacoemulsification on the Macular Changes in Patients with Neovascular Age-related Macular Degeneration
The macula has a very high concentration of photoreceptor cells - the cells that detect light. They send signals to the brain, which interprets them as images.
- Trial name
- it does not (NCT06759597)
- Volunteers
- 50 people
- Sponsor
- Assiut University
Age Related Macular Degeneration, Pigment Epithelial Detachment
On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
The purpose of this study is to evaluate the efficacy and safety of intravitreal aflibercept injection in a population of neovascular AMD patients that have been previously treated with 2.0 mg ranibizumab for persistent PEDs.
- Trial name
- ROLL (NCT01670162)
- Testing
- Aflibercept
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tennessee Retina
Wet Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
- Trial name
- DAYBREAK (NCT06556368)
- Testing
- Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 667 people
- Sponsor
- Kodiak Sciences Inc
Age-related Macular Degeneration (ARMD)
Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment
The treatment landscape for neovascular AMD has evolved with various anti-VEGF agents since 2006. Ranibizumab initially led the way, but its limited efficacy in reducing retinal edema paved the way for aflibercept in 2011, which…
- Trial name
- NCT06683950
- Testing
- Aflibercept 8mg
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Kim's Eye Hospital
Neovascular Age-related Macular Degeneration
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
- Trial name
- ShORe (NCT04757610)
- Testing
- 2.0 mg OPT-302, 0.5 mg ranibizumab
- Where
- 191 sites in United States, Argentina and 22 more
- Volunteers
- 986 people
- Sponsor
- Opthea Limited
Neovascular Age-Related Macular Degeneration (nAMD), Treatment-naïve
Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD) is a one of the leading causes of irreversible vision loss among the elderly in developed countries.
- Trial name
- NCT06890026
- Testing
- Faricimab Injection [Vabysmo]
- Where
- Denmark
- Volunteers
- 742 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
- Trial name
- VOYAGER (NCT05476926)
- Testing
- Faricimab, Port Delivery System with Ranibizumab
- Where
- 299 sites in United States, Argentina and 27 more
- Volunteers
- 6,000 people
- Sponsor
- Hoffmann-La Roche
Neovascular Age-related Macular Degeneration
Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescription Data: REALIZE Study
REALIZE was a single-arm retrospective cohort study which described treatment patterns with brolucizumab, including treatment intervals between anti-vascular endothelial growth factor (VEGF) injections before and after a switch…
- Trial name
- NCT06021366
- Where
- Portugal
- Volunteers
- 2,089 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration
A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
The purpose of this study was to compare the development of new geographic atrophy in patients with wet Age-related Macular Degeneration (AMD) when treated with either ranibizumab or aflibercept over 24 months.
- Trial name
- RIVAL (NCT02130024)
- Testing
- Ranibizumab 0.5 mg, Aflibercept 2.0 mg
- Where
- 22 sites in Australia
- Volunteers
- 281 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Macular Degeneration
Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration
The main goal is to study way that aflibercept injection behaves in the eye and in the body of patients with wet macular degeneration, in patients who have had previous vitreous removal surgery.
- Trial name
- DRAW (NCT02204683)
- Testing
- Aflibercept
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Nebraska
Choroidal Neovascularization, Macular Edema
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.
- Conditions
- Choroidal Neovascularization, Macular Edema, Glaucoma, Neovascular, Diabetic Retinopathy
- Trial name
- ECLIPSE (NCT01908816)
- Testing
- ranibizumab
- Where
- 39 sites in France
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.
- Trial name
- NCT02181504
- Testing
- abicipar pegol, ranibizumab
- Where
- 11 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Allergan